Search research articles
Contact Us
Filters
Showing results (1-10 of 147) with videos related to
Page
of 15
Sort By:
Clinical Breast Cancer
|
July 15, 2009
Treatment of HER2-positive metastatic breast cancer following initial progression
Ingrid A Mayer
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 22, 2015
Advanced hormone-sensitive breast cancer: overcoming resistance
Ingrid A Mayer
Cancer Treatment and Research
|
October 8, 2005
Targeting cytokine receptors and pathways in the treatment of breast cancer
Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
June 5, 2014
Subtyping of triple-negative breast cancer
Ingrid A Mayer
Current Breast Cancer Reports
|
February 17, 2016
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Ingrid A Mayer
Clinical Breast Cancer
|
July 1, 2010
Antiangiogenic therapies in early-stage breast cancer
Christina Derleth, Ingrid A Mayer
Current Oncology Reports
|
May 27, 2015
Optimizing the use of neoadjuvant endocrine therapy
Laila S Agrawal, Ingrid A Mayer
Current Breast Cancer Reports
|
November 25, 2014
Molecular Heterogeneity of Triple Negative Breast Cancer
Vandana G Abramson, Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
February 7, 2015
Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Laila Saied Agrawal, Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
August 19, 2021
New targets in endocrine-resistant hormone receptor-positive breast cancer
Laura C Kennedy, Ingrid A Mayer
Page
of 15
Search research articles
Search
Showing results (1-10 of 147) with videos related to
Sort By:
Page
of 15
Clinical Breast Cancer
|
July 15, 2009
Treatment of HER2-positive metastatic breast cancer following initial progression
Ingrid A Mayer
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 22, 2015
Advanced hormone-sensitive breast cancer: overcoming resistance
Ingrid A Mayer
Cancer Treatment and Research
|
October 8, 2005
Targeting cytokine receptors and pathways in the treatment of breast cancer
Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
June 5, 2014
Subtyping of triple-negative breast cancer
Ingrid A Mayer
Current Breast Cancer Reports
|
February 17, 2016
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Ingrid A Mayer
Clinical Breast Cancer
|
July 1, 2010
Antiangiogenic therapies in early-stage breast cancer
Christina Derleth, Ingrid A Mayer
Current Oncology Reports
|
May 27, 2015
Optimizing the use of neoadjuvant endocrine therapy
Laila S Agrawal, Ingrid A Mayer
Current Breast Cancer Reports
|
November 25, 2014
Molecular Heterogeneity of Triple Negative Breast Cancer
Vandana G Abramson, Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
February 7, 2015
Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Laila Saied Agrawal, Ingrid A Mayer
Clinical Advances in Hematology & Oncology : H&O
|
August 19, 2021
New targets in endocrine-resistant hormone receptor-positive breast cancer
Laura C Kennedy, Ingrid A Mayer
Page
of 15